投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □一对一沟通 ☑ 其他（电话会议） 参与单位名称及人员 姓名 华西医药-程仲瑶 易方达-郭杰、余欣鑫、廖敏华、邓子晗、胡可冕 时间 2026 年 1 月 21 日 地点 集团总部办公大楼 上市公司接待人员 证券事务代表-李孟珏 投资者关系管理-张昱、杨可欣 投资者关系活动主要 内容介绍 了解公司生产经营情况 附件清单 会议记录 日期 2026 年 1 月 21 日星期三 1 / 1 投资者调研会议记录表 编号：1-2601-01 云南白药集团股份有限公司 ...

证券之星消息，1月23日中药板块较上一交易日上涨0.28%，*ST长药领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流出5.1亿元，游资资金净流出5225.91万元，散户资金净流 入5.62亿元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | 2925.96万 | 3.91% | 124.39万 | 0.17% | -3050.36万 | -4.07% | | 002390 | 信邦制药 | 1707.83万 | 9.03% | -877.49万 | -4.64% | -830.34万 | -4.39% | | 600750 江中药业 | | 1112.58万 | 4.76% | 719.17万 | 3.08% | -- 1831. ...

Core Viewpoint - The report highlights the significant inflow of main capital into various stocks, with specific companies showing remarkable performance in terms of net capital inflow and stock price changes [1][2]. Group 1: Main Capital Inflow - A total of 88 stocks have experienced a net inflow of main capital for five consecutive days or more, indicating strong investor interest [1]. - Hangzhou Bank leads with 16 consecutive days of net inflow, followed by Yunnan Baiyao with 14 days [1]. - Midea Group has the highest total net inflow amounting to 1.582 billion yuan over seven days, while Hangzhou Bank follows closely with 1.489 billion yuan over 16 days [1]. Group 2: Performance Metrics - The stock with the highest net inflow ratio relative to trading volume is Fenglong Co., which has surged by 359.76% over the past 16 days [1]. - Other notable stocks include Guotai Junan Securities with a net inflow of 1.109 billion yuan over 11 days and China Ping An with 1.074 billion yuan over six days, although their stock prices have seen declines of 2.46% and 3.28% respectively [1]. - The report includes a detailed table of stocks with their respective net inflow amounts, inflow ratios, and cumulative price changes, providing a comprehensive overview of market trends [1][2].

Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the 28 sectors in the Shenwan classification experiencing gains, led by the construction materials and defense industries, which increased by 4.09% and 3.23% respectively [1] - The beauty and banking sectors saw the largest declines, with decreases of 0.76% and 0.43% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 21.612 billion yuan, with 12 sectors experiencing net inflows [1] - The telecommunications sector had the highest net inflow, amounting to 8.019 billion yuan, and it rose by 2.83% [1] - The defense industry also saw significant inflow, with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - The electronics sector faced the largest net outflow, totaling 13.206 billion yuan, followed by the power equipment sector with an outflow of 7.206 billion yuan [1] Pharmaceutical and Biological Industry Performance - The pharmaceutical and biological sector declined by 0.42%, with a net capital outflow of 3.027 billion yuan [2] - Out of 478 stocks in this sector, 253 rose while 204 fell, with 2 stocks hitting the daily limit up [2] - The top three stocks with the highest net inflow were Sanbo Brain Science (1.42 billion yuan), Yunnan Baiyao (667.561 million yuan), and Innovation Medical (637.008 million yuan) [2] - The sector's outflow was led by Hengrui Medicine, which saw a net outflow of 372.7538 million yuan, followed by Xingqi Eye Medicine and Aidi Pharmaceutical with outflows of 208.3529 million yuan and 121.6946 million yuan respectively [3]

证券时报·数据宝统计，截至1月21日收盘，深沪北共101只个股连续5日或5日以上主力资金净流入。杭 州银行等连续15日主力资金净流入，排名第一；云南白药连续13日主力资金净流入，位列第二。从主力 资金净流入总规模来看，德明利主力资金净流入金额最大，连续6天累计净流入15.50亿元，杭州银行紧 随其后，15天累计净流入14.39亿元。从主力资金净流入占成交额的比例来看，锋龙股份占比排名居 首，该股近15日上涨317.94%。（数据宝） 连续5日或以上主力资金净流入个股排名 | 证券代 | 证券简 | 主力资金净流入 | 主力资金净流入金额 | 主力资金净流入比例 | 累计涨跌幅 | | --- | --- | --- | --- | --- | --- | | 码 | 称 | 天数 | （亿元） | （%） | （%） | | 001309 | 德明利 | 6 | 15.50 | 6.77 | 22.39 | | 600926 | 杭州银 行 | 15 | 14.39 | 9.88 | -0.65 | | 000333 | 美的集 团 | 6 | 11.55 | 6.11 | 2.07 | | 000776 | ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.39% on January 21, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - *ST Changyao: Closed at 0.64, up 20.75% with a trading volume of 519,700 shares and a turnover of 32.17 million yuan [1] - Tianmu Pharmaceutical: Closed at 22.29, up 8.47% with a trading volume of 128,100 shares and a turnover of 282 million yuan [1] - Wanbangde: Closed at 17.82, up 5.13% with a trading volume of 196,800 shares and a turnover of 34.2 million yuan [1] - Conversely, Zhongsheng Pharmaceutical saw a decline of 4.26%, closing at 21.12 with a trading volume of 685,100 shares and a turnover of 144.9 million yuan [2] Capital Flow - The traditional medicine sector experienced a net outflow of 281 million yuan from major funds, while retail investors saw a net inflow of 78.63 million yuan [2] - Major funds showed significant net inflows in stocks such as Yunnan Baiyao, which had a net inflow of 78.68 million yuan, and Wanbangde with a net inflow of 22.17 million yuan [3]

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Core Insights - The Shanghai Municipal Market Supervision Administration conducted a quality inspection of toothpaste products in 2025, with 30 batches tested and no non-compliance found [2]. Group 1: Inspection Results - The inspection was based on the JJF 1070-2023 standards for measuring the net content of packaged goods, focusing on net content labeling and actual net content [2]. - All tested toothpaste products met the relevant standards, indicating a high level of compliance in the market [2]. Group 2: Product Details - Various brands and types of toothpaste were included in the inspection, such as: - DARLIE's mineral toothpaste (120g) from Haolai Chemical [2] - Yunnan Baiyao's sensitive toothpaste (110g) from Yunnan Baiyao Group [2] - Colgate's 3D whitening toothpaste (90g) from Procter & Gamble [2] - The inspection covered products sold in multiple retail locations, including shopping malls and e-commerce platforms [2].

Core Viewpoint - The 2025 China Enterprise ESG "Golden Responsibility Award" aims to recognize companies that have made significant contributions to ESG (Environmental, Social, and Governance) practices, with over 5,000 enterprises participating in the evaluation process [1][4]. Group 1: ESG Award Overview - The award was launched in November 2025 by Sina Finance ESG Rating Center, focusing on promoting sustainable development and responsible investment [1][4]. - The award emphasizes the importance of responsibility in ESG practices, symbolizing that responsibility is as valuable as gold [1][4]. - The evaluation process included comprehensive performance assessments, professional scoring, and online voting, culminating in the announcement of the award winners after three months of competition [1][4]. Group 2: Award Winners - The "Best Responsibility Initiative Award" was awarded to ten companies, including: - Fenghuo Communication - Wens Foodstuff Group - Haitian Flavoring and Food - Aier Eye Hospital - Yunnan Baiyao - Anker Innovation - Jinfa Technology - Huatai Securities - Seres - Hainengda [2][5]. - The award committee congratulated the winners and expressed hope that these companies will lead by example in enhancing their ESG capabilities and contribute to China's high-quality development [2][5]. Group 3: ESG Rating Center Introduction - The Sina Finance ESG Rating Center is the first Chinese platform dedicated to ESG information and ratings, promoting sustainable development and responsible investment [3][6]. - The center aims to establish ESG evaluation standards suitable for China's characteristics and enhance corporate ratings [3][6]. - It also publishes multiple ESG innovation indices to provide investors with more options regarding corporate ESG performance [3][6].

Core Insights - Yunnan Baiyao Group's subsidiary, Guoyao Innovation, launched the proprietary traditional Chinese medicine product "Shulianan® Shulianan Capsules" on JD Health, targeting chronic non-bacterial prostatitis in men suffering from lower urinary tract symptoms [1][4] - The product aims to address the high prevalence of chronic prostatitis, particularly in men aged 30-39 and 60-69, where the incidence rates are 34.4% and 36.4% respectively [3] - The launch reflects Yunnan Baiyao's commitment to the "Healthy China" strategy and its focus on providing effective health solutions, showcasing its strategy of "big products + secondary development" [4] Product Details - Shulianan Capsules are derived from the traditional Yi medicine "Song Lou Zheng" and utilize the single herb "Da Fa Biao" to treat symptoms such as frequent urination, urgency, and pain associated with chronic non-bacterial prostatitis [3] - The development of Shulianan Capsules is based on modern pharmacology and clinical evaluation, validating its efficacy through systematic pharmacological and clinical research [3] Strategic Collaboration - The launch on JD Health represents a deepening of the strategic partnership established in April 2025, focusing on supply chain, retail, and innovative marketing collaboration [4] - JD Health will leverage its full-channel network to enhance the product's accessibility, integrating online consultations and patient education to create a comprehensive management experience [4] - Future initiatives will explore digital marketing, patient education projects, and the integration of online and offline services to develop a user-centered chronic disease management ecosystem [4]